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Abstract
InSite is North Americas first supervised injection site and a landmark public heath initiative
operating in Vancouver since 2003. The program is a vital component of that cities internationally
recognized harm reduction approach to its serious problems with drugs, crime, homelessness and
AIDS. InSite currently operates under a waiver of Federal rules that allow it to provide services as
a research project. An extensive evaluation has produced very positive results for thousands of
users. Normally such strong evidence documenting the successes of such a program, and the
medical and public health significance of these positive outcomes, would be the basis for celebration
and moves to expand the model and provide similar services elsewhere in Canada.
Instead, there is a distinct possibility that InSite will be closed by the newly elected Canadian Prime
Minister Paul Harper – a conservative who has traveled to the US to visit George WQ Bush and
come back antagonistic to harm reduction in all its forms. Because InSites federal waiver is expiring
and up for renewal in September, the fear is that Mr. Harpers will not renew the approval and that
the program will be forced to close down. The risks associated with the potential closure of InSite
need to be fully understood. This editorial lays out these public health risks and the associated
economic impact if InSite were to be closed.
In addition to preventable deaths and disease, InSites closure will cost Vancouver and British
Columbia between $3.8 and $ 8.8 million in preventable health care expenses over the next two
years.
Background
Insite is North America's first supervised injection site – a
landmark public heath initiative that has been operating
since 2003 in Vancouver's Downtown Eastside. The pro-
gram is a vital component of that cities internationally rec-
ognized harm reduction strategy addressing it's serious
problems with drugs, crime, homelessness and AIDS.
Insite  serves more than 7,200 registered clients with
15,000 to 20,000 visits each month – all active intrave-
nous users at the highest risk for HIV transmission and
overdose. Insite has now been providing vital health care
and referral services to drug users in Vancouver's down-
town eastside for over two years and the results are
impressive. (See Additional file 1)
InSite has been the subject of rigorous, independent
research and evaluation since it opened its doors and the
data collected so far are compelling in their implications.
These studies convincingly demonstrate Insite's positive
impact as a life saving public health program that does not
increase drug use nor produce any adverse outcomes. As
published in leading peer-reviewed journals,(see Addi-
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tional file 2) these studies uniformly and persuasively find
that the Insite program is producing important public
heath and social outcomes and exceeding all of its targets.
InSite's three-year demonstration and research program
provides the community, government, other health care
agencies, and the global research community with much
needed data about the efficacy of such a facility and its
consequences both for health outcomes related to drug
use and (of equal importance) for its local community's
sense of safety and security. Much of that research has
been conducted by investigators at the British Columbia
Centre for Excellence in HIV/AIDS and published in lead-
ing peer-reviewed journals.
The principal research findings are that:
￿ InSite is leading to increased admissions to local detoxi-
fication programs and addiction treatment. [1]
￿ InSite has not led to an increase in drug-related crime,
rates of arrest for drug trafficking, assaults and robbery
were similar after the facility's opening, and rates of vehi-
cle break-ins/theft declined significantly. [2]
￿ InSite has reduced the number of people injecting in
public and the amount of injection-related litter in the
downtown eastside. [3]
￿ InSite is attracting the highest-risk users – those more
likely to be vulnerable to HIV infection and overdose, and
who were contributing to problems of public drug use and
unsafe syringe disposal. [4]
￿ InSite has reduced overall rates of needle sharing in the
community, and among those who used the supervised
injection site for some, most or all of their injections, 70%
were less likely to report syringe sharing. [5]
￿ Nearly one-third of InSite users received information
relating to safer injecting practices. Those who received
help injecting from fellow injection drug users on the
streets were more than twice as likely to have received
safer injecting education at InSite. [6]
￿ InSite is not increasing rates of relapse among former
drug users, nor is it a negative influence on those seeking
to stop drug use. [7]
Since it came into being, Insite has reached over 7200 high
risk injection drug users (usually those not otherwise in
treatment) and decreased public injection, reduced needle
sharing, prevented bacterial infections and overdose
deaths; increased the use of withdrawal management
(detoxification or tapering off drugs) and provided other
addiction harm reduction and treatment services for over
4000 clients; while also increasing referral to other com-
munity resources that can help active drug users – e.g.
mainstream medical, and mental health services. In addi-
tion InSite has not increased crime, public disorder, or
drug dealing in its neighborhood, not led to increased
relapse among former drug users, nor been a negative
influence on those seeking to stop drug use altogether.
The threat to close InSite
Normally such strong evidence documenting the many
successes of such a pilot program, and the medical and
public health significance of its very positive outcomes,
would be the basis for celebration and lead to moves to
expand the model and provide similar services elsewhere
in Canada. Instead, there is a distinct possibility that InSite
will be closed by the newly elected Canadian Prime Min-
ister Paul Harper – a conservative who has traveled to the
US to visit George W. Bush and come back to Ottawa hos-
tile to harm reduction in all its forms – a sentiment that
originates in Washington DC and appears to function as a
loyalty test for international drug policies worldwide.
The InSite program operates under a waiver of Canadian
Federal health rules that allow it to provide its services as
a research project. Because InSites federal waiver is expir-
ing in September, many fear that Mr. Harper will not
renew its approval and that the program will be forced to
close down. The risks associated with any potential clo-
sure of InSite need to be fully understood.
In addition to abandoning the care of so many of Vancou-
ver's drug users and the needless pain and suffering this
will inflict on them and their loved ones, it is possible to
project a number of very specific consequences of any fail-
ure to continue it. By utilizing the data from the InSite
studies that have been published in the peer review litera-
ture, we can predict a set of adverse outcomes and their
related economic costs – all now prevented by InSite.
These include:
Failure to Prevent 22 overdose deaths: based on a 5% mortal-
ity rate among 453 overdoses treated at In Site, if these had
occurred in the community. [1]
Failure to Prevent 112 hospitalizations for non – lethal over-
dose deaths: based on a 25% hospitalization rate (includ-
ing psychiatric) among 453 overdoses treated at In Site, if
these overdoses occurred in the community. At a 2–5 day
average length of stay for each such admission, this yields
224–560 extra hospital bed days and estimated costs (at $
500/day) would total $112,000 to $280,000 [2]
Failure to Prevent 2000 Emergency medical visits for injection
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other bacterial infections associated with unsafe injecting
cost $1000 – $3000 per incident – annual savings $2 – 6,
000,000) [3]
Failure to Prevent 100 Hospitalizations due to bacterial infec-
tions: Based on 5% rate of hospitalization for the 2000
bacterial infections seen at Insite. Each such admission
has an average length of stay of 15 – 20 days with a cost
(at $500 per day) of $7500 – 15,000 per admission and a
cost per year of $ 750,000 – 1 million [4]
Failure to make 100 referrals to Methadone treatment: with
savings of $10,000/year/client in criminal justice and
medical costs = $ 1 million [5]
The economic cost of closing InSite will far exceed the cost
of operating it – by millions of dollars per year. The avail-
able data on the economic impact of Insite (in addition to
the preventable deaths and disease that the programs clo-
sure will cause) indicate that the end of the program will
cost Vancouver and British Columbia between $
3,862,000 and $8,780,000 in additional health care
expenses over the next two years. In addition to the
increased demands that InSites closure would place on
already scarce health care resources, Insites termination
would also lead to thousands of additional arrests (which
cost more than $10,000 apiece) court adjudications
(another $10,000) and all the jail and probation time
(not to mention public displeasure) associated with a
return to public drug use by this large group.
As AIDS associated with injecting drug use continues to
spread and ignites new regional epidemics of HIV – most
dramatically evident today in the former Soviet Union –
we need more InSites, not fewer ones. Vancouver's and
Canada's struggle to develop and maintain innovative
public health programs that more effectively deal with
drugs and AIDS are ones we in the international public
health community all share. But the end of InSite would
be a setback not only for Vancouver and Canada – it
would be a great loss for all of our efforts to build effective
and sustainable public health initiatives for dealing with
addiction and AIDS prevention everywhere in the world.
By granting renewal of InSite's federal approval, the Cana-
dian federal government will be acting in the best interest
not only of the citizens of Vancouver, but also in the best
interests of all Canadians struggling to find effective
responses to the nations daunting problems of AIDS and
addictions. And, because of the high esteem in which
Canadian public health is held worldwide, the actions of
the Canadian government in regard to InSite will have a
strong effect elsewhere. If negative they will embolden the
opponents of harm reduction globally – reinforcing a
dangerous trend to put some short term perceived politi-
cal advantage ahead of public health evidence.
As the research on InSite makes so readily apparent, the
failure to sustain InSite will most certainly condemn
scores of Canadians to premature deaths (from drug over-
dose and AIDS) and thousands more to lives of increased
disease, degradation, and criminal activity – all at inordi-
nate public expense. The choice seems clear.
Additional material
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Additional file 1
a brochure from Vancouver Coastal Health which gives an overview of the 
program and some examples of its work in the Downtown Eastside com-
munity.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7517-3-24-S1.pdf]
Additional file 2
a review which summarizes these research studies.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
7517-3-24-S2.doc]